Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.

Siberry GK, Williams PL, Lujan-Zilbermann J, Warshaw MG, Spector SA, Decker MD, Heckman BE, Demske EF, Read JS, Jean-Philippe P, Kabat W, Nachman S; IMPAACT P1065 Protocol Team.

Pediatr Infect Dis J. 2010 May;29(5):391-6. doi: 10.1097/INF.0b013e3181c38f3b.

2.

Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children.

Siberry GK, Warshaw MG, Williams PL, Spector SA, Decker MD, Jean-Philippe P, Yogev R, Heckman BE, Manzella A, Roa J, Nachman S, Lujan-Zilbermann J; IMPAACT P1065 Protocol Team.

Pediatr Infect Dis J. 2012 Jan;31(1):47-52. doi: 10.1097/INF.0b013e318236c67b.

3.

A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.

McVernon J, Nolan T, Richmond P, Reynolds G, Nissen M, Lambert SB, Marshall H, Papa T, Rehm C.

Pediatr Infect Dis J. 2012 Jan;31(1):e15-23. doi: 10.1097/INF.0b013e31823e1e34.

PMID:
22094636
4.

Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia.

Ilyina N, Kharit S, Namazova-Baranova L, Asatryan A, Benashvili M, Tkhostova E, Bhusal C, Arora AK.

Hum Vaccin Immunother. 2014;10(8):2471-81. doi: 10.4161/hv.29571.

5.

Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus.

Lujan-Zilbermann J, Warshaw MG, Williams PL, Spector SA, Decker MD, Abzug MJ, Heckman B, Manzella A, Kabat B, Jean-Philippe P, Nachman S, Siberry GK; International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1065 Protocol Team.

J Pediatr. 2012 Oct;161(4):676-81.e2. doi: 10.1016/j.jpeds.2012.04.005. Epub 2012 May 22.

6.

Meningococcal serogroup A, C, W, and Y serum bactericidal antibody profiles in Hajj pilgrims.

Memish ZA, Yezli S, Almasri M, Assiri A, Turkestani A, Findlow H, Bai X, Borrow R.

Int J Infect Dis. 2014 Nov;28:171-5. doi: 10.1016/j.ijid.2014.09.005. Epub 2014 Oct 12.

7.

Meningococcal group A, C, Y and W-135 conjugate vaccine.

Harrison LH, Mohan N, Kirkpatrick P.

Nat Rev Drug Discov. 2010 Jun;9(6):429-30. doi: 10.1038/nrd3194.

PMID:
20514064
9.

Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT.

Findlow H, Borrow R.

Adv Ther. 2013 May;30(5):431-58. doi: 10.1007/s12325-013-0032-5. Epub 2013 May 28. Review.

PMID:
23712402
11.

Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source.

Gill CJ, Ram S, Welsch JA, Detora L, Anemona A.

Vaccine. 2011 Dec 9;30(1):29-34. doi: 10.1016/j.vaccine.2011.10.068. Epub 2011 Nov 7.

12.

Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients.

Wyplosz B, Derradji O, Hong E, François H, Durrbach A, Duclos-Vallée JC, Samuel D, Escaut L, Launay O, Vittecoq D, Taha MK.

Transpl Infect Dis. 2015 Apr;17(2):322-7. doi: 10.1111/tid.12359. Epub 2015 Mar 6.

PMID:
25645691
13.

Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.

Pace D.

Expert Rev Vaccines. 2009 May;8(5):529-42. doi: 10.1586/erv.09.18. Review.

PMID:
19397410
14.
15.
16.
17.

Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005.

Ceyhan M, Yildirim I, Balmer P, Riley C, Laher G, Andrews N, Borrow R, Kurt N, Turgut M, Aydogan A, Ecevit C, Uysal G, Schultze V.

Vaccine. 2007 Oct 10;25(41):7233-7. Epub 2007 Aug 1.

PMID:
17707957
18.

Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.

Borja-Tabora CF, Montalban C, Memish ZA, Boutriau D, Kolhe D, Miller JM, Van der Wielen M.

BMC Infect Dis. 2015 Oct 6;15:409. doi: 10.1186/s12879-015-1138-y.

19.
20.

Immunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in Previously Immunized HIV-Infected Children and Youth.

Warshaw MG, Siberry GK, Williams P, Decker MD, Jean-Philippe P, Lujan-Zilbermann J.

J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):e69-e74. doi: 10.1093/jpids/piw094.

PMID:
28339668

Supplemental Content

Support Center